Literature DB >> 19154467

A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity.

Marcella M Baldewijns1, Tania Roskams, Vera Ballet, Gert G Van den Eynden, Steven J Van Laere, Ilse Van der Auwera, Evelyne Lerut, Adriaan P De Bruïne, Victor L Thijssen, Peter B Vermeulen, Hein van Poppel.   

Abstract

OBJECTIVE: To assess ongoing lymphangiogenesis in renal cell carcinoma (RCC) by histomorphometry and by quantifying mRNA expression levels of lymphangiogenesis-related factors.
MATERIALS AND METHODS: Using D2-40 antibody as a lymphatic marker, lymph vessels were counted in tissue sections of 150 clear-cell RCCs (ccRCC) and 61 non-neoplastic controls, using the Chalkley method, which measures the relative lymph vessel area (LVA). Double-staining with Ki67 and D2-40 was used to assess active lymphangiogenesis. In a subset of 25 ccRCCs and nine non-neoplastic controls mRNA expression levels of lymphangiogenic factors were determined by real-time quantitative reverse transcription-polymerase chain reaction.
RESULTS: LVA was higher in normal renal tissue than in both intra- and peri-tumoral LVA (P < 0.001). LVA in the tumour periphery was higher than in the tumour parenchyma (P < 0.001). Lymphatic endothelial cell proliferation (LECP) was identified in 8.2% of the control sections and was higher than the intratumoral LECP fraction (LECP%, 2.6%; P = 0.02) and the peritumoral LECP% (6.5%; P > 0.05). Compared with controls, ccRCC specimens had higher mRNA expression levels of vascular endothelial growth factor (VEGF)-A and VEGF-C, but lower expression levels of VEGF-D and Prox-1 (all P < 0.001).
CONCLUSION: Our results show that there is only limited ongoing lymphangiogenesis in ccRCC. Given that several growth factors stimulate both angiogenesis and lymphangiogenesis, our observation indirectly indicates that haemangiogenesis predominates in ccRCC. This finding might provide better understanding of why ccRCCs prefer haematogenous dissemination to lymphatic spread.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154467     DOI: 10.1111/j.1464-410X.2008.08272.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

Review 1.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

2.  The clinical significance of lymphangiogenesis in renal cell carcinoma.

Authors:  Paweł Dębiński; Janusz Dembowski; Paweł Kowal; Tomasz Szydełko; Anna Kołodziej; Bartosz Małkiewicz; Krzysztof Tupikowski; Romuald Zdrojowy
Journal:  Med Sci Monit       Date:  2013-07-24

3.  VEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells.

Authors:  Manon Penco-Campillo; Yannick Comoglio; Álvaro Javier Feliz Morel; Rita Hanna; Jérôme Durivault; Magalie Leloire; Bastien Mejias; Marina Pagnuzzi; Amandine Morot; Fanny Burel-Vandenbos; Matthew Selby; Daniel Williamson; Steven C Clifford; Audrey Claren; Jérôme Doyen; Vincent Picco; Sonia Martial; Gilles Pagès
Journal:  Commun Biol       Date:  2020-10-16

Review 4.  The Role of PROX1 in Neoplasia: A Key Player Often Overlooked.

Authors:  Evangelia Ntikoudi; Alexandros Pergaris; Stylianos Kykalos; Ekaterini Politi; Stamatios Theocharis
Journal:  Diagnostics (Basel)       Date:  2022-07-04

5.  Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.

Authors:  Charles S Harmon; Samuel E DePrimo; Robert A Figlin; Gary R Hudes; Thomas E Hutson; M Dror Michaelson; Sylvie Négrier; Sindy T Kim; Xin Huang; J Andrew Williams; Tim Eisen; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-13       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.